News

UC San Diego Health Awarded for Efforts to Reduce Health Disparities

UC San Diego Health has won the 2022 California Association of Public Hospitals and Health Systems (CAPH) Quality Leaders Award in the health equity category for its  same-day outpatient infusion program, which seeks to mitigate healthcare disparities in sickle cell disease (SCD). Each year, the CAPH recognizes initiatives by…

ESCAPE, Way of Safely Preparing for Sickle Cell Gene Editing, Advancing

New preclinical data support the ability of the ESCAPE platform, an approach Beam Therapeutics is advancing, to more safely prepare people with sickle cell disease (SCD) for gene-editing treatments now in development. Notably, these studies represent the first in vivo data for ESCAPE — that is, the experimental platform’s first evaluation in living…

Gene-editing Therapy EDIT-301 Promising in 1st RUBY Patients

The experimental gene-editing therapy EDIT-301 appears to be working largely as expected in the first two sickle cell disease (SCD) patients treated as part of the Phase 1/2 RUBY trial, according to new data shared by the therapy’s developer, Editas Medicine. “These promising clinical results from the RUBY…